Subject:
- Active Sustance: Valoctocogene roxaparvovec
- Name: Roctavian®
- Therapeutic area: Hemophilia A
- Pharmaceutical company: BioMarin International Ltd.
Time table:
- Start: 15.09.2022
- Publication of assessment: 15.12.2022
- End of public hearing: 05.01.2023
- Final decision by G-BA: beginning of March 2023
Comparative therapy:
- No comparative therapy due to orphan drug designation